Search Results - "Sulgey, Gauthami"
-
1
The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ ® ) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection
Published in Vaccines (Basel) (07-08-2024)“…The first vaccine against chikungunya virus (CHIKV) was recently licensed in the U.S., Europe, and Canada (brand IXCHIQ , referred to as VLA1553). Other…”
Get full text
Journal Article -
2
Nonreciprocity in CHIKV and MAYV Vaccine-Elicited Protection
Published in Vaccines (Basel) (01-09-2024)“…Chikungunya virus (CHIKV) is a pathogenic arthritogenic alphavirus responsible for large-scale human epidemics for which a vaccine was recently approved for…”
Get full text
Journal Article -
3
Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond
Published in Monoclonal antibodies in immunodiagnosis and immunotherapy (01-04-2021)“…The dawn of the 20th century saw the formative years of developments in immunology. In particular, immunochemistry, specifically pertaining to antibodies, was…”
Get more information
Journal Article -
4
Immunogenicity of a Candidate Ebola Hemorrhagic Fever Vaccine in Mice Based on Controlled In Vitro Expression of Ebolavirus Glycoprotein
Published in Viral immunology (01-09-2018)“…Ebolavirus (EBOV) is the etiology of Ebola hemorrhagic fever (EHF). A major EHF outbreak in 2014-2015 in West Africa claimed >11,000 lives. A licensed vaccine…”
Get more information
Journal Article